Product Description: Ligelizumab (QGE 031) is a humanized high-affinity monoclonal anti-IgE antibody. Ligelizumab can be used for the research of chronic spontaneous urticarial[1].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Gasser P, et al. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab. Nat Commun. 2020 Jan 8;11(1):165.